Article

Sponsored Content

Bright Skies, Big Challenges: Orphan Drugs and Rare Diseases

 

 

External Link - PE_Orphan-Drugs-and-Rare-Diseases_6-1-2017.pdf

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe Now!
Related Videos
Harshit Jain
Derrick Gastineau
Noah Nasser
Related Content
Stock.adobe.com
August 29th 2025

Replicate Bioscience Announces Partnership with Novo Nordisk Aimed at Unlocking Self-Replicating RNA Therapies

Nicholas Jacobus
The Rx for High-Performance Leadership: Cutting Through the Chaos
August 29th 2025

The Rx for High-Performance Leadership: Cutting Through the Chaos

Michael Christel
Robert F. Kennedy Jr.
August 29th 2025

Susan Monarez Rejects Removal as CDC Director Even After White House Steps In

Mike Hollan
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
August 29th 2025

Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research

Miranda Schmalfuhs
Stock.adobe.com
August 29th 2025

FDA Accepts New Drug Application for Gadoquatrane

Nicholas Jacobus
Credit: Tada Images | stock.adobe.com, The FDA has authorized the use of updated COVID-19 vaccines for the upcoming fall season, with eligibility limited to adults aged 65 years and older as well as individuals who have at least one underlying medical condition that places them with a high risk for severe COVID-19
August 29th 2025

FDA Authorizes New COVID Vaccines with Restrictions on Eligibility

Davy James